癌症單株抗體的合作與授權協議（2016-2026 年）

癌症單株抗體交易領域的權威基準

癌症單株抗體領域的合作是由生物目標療法驅動的，其合約結構反映了抗體療法在各種腫瘤適應症中的不斷發展。

本報告對 650 多項與癌症單株抗體相關的合作和許可協議進行了全面系統的分析，清楚地展示了整個市場夥伴關係的設計、談判和執行方式，並以證據為基礎進行了闡述。

清楚了解市場標準

本報告對癌症單株抗體領域的合約實際是如何建構的提供了精確的理解。

• 類似交易的可靠基準
• 對相關合約中的預付款、里程碑付款和特許權使用費結構進行詳細分析
• 定義切合實際的市場參數
• 清晰洞察基於研發階段、抗體類型和合作夥伴情況的合約條款差異。
• 支持基於證據的評估和合約結構確定。
• 讓內部討論基於實際交易數據，而不是僅基於假設。
• 了解主要公司的交易方式
• 在競爭激烈、創新主導的癌症領域，可視化合作夥伴的行為模式和重複的合約結構。
• 完全透明地了解合約的結構和執行情況
• 本報告超越了表面的合約數據，提供了對底層合約文件的訪問，以便詳細了解實際協議是如何構建的。

這包括以下內容：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和付款條款
• 關鍵合約條款和保護措施
• 這種透明度對於理解單株抗體合作中價值、風險和控制權的分配至關重要。在涉及差異化生物製藥和標靶治療策略的領域，其重要性更為顯著。
• 專為實際業務發展和策略應用而設計。

本報告廣泛用於以下用途：

• 癌症生技藥品交易的結構化和基準分析
• 在清晰的市場環境下準備談判
• 評估許可和合作開發機會
• 利用可靠且可解釋的數據支持內部策略規劃

本報告內容：

• 超過 650 項與癌症單株抗體相關的合作和許可協議。
• 財務條款，包括預付款、里程碑付款和特許權使用費（如已揭露）。
• 可全文搜尋的合約目錄（依公司、治療領域及抗體類型）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 合約趨勢、重大交易和活躍合約方分析。
• 用於交易癌症單株抗體的可靠依證
• 本報告結合了全面的合約資料覆蓋和詳細的合約層面分析，為在癌症單株抗體領域建立、談判和評估夥伴關係關係提供了可靠的、依證的參考。

目錄

執行摘要

第1章：引言

第2章：癌症單株抗體的交易趨勢

• 過去幾年在癌症單株抗體的合作
• 癌症單株抗體領域最活躍的交易方
• 癌症單株抗體合約：按合約類型分類
• 癌症單株抗體收縮：依治療領域分類
• 癌症單株抗體合約：按行業分類
• 癌症單株抗體合約的條款和條件
  • 標題金額
  • 預付款
  • 里程碑付款
  • 權利金費率

第3章 主要癌症單株抗體合約

• 按合約價值排名的暢銷癌症單株抗體合約

第4章：癌症單株抗體這最活躍領域的締約方

• 癌症單株抗體這一最活躍領域的締約方
• 癌症單株抗體領域最活躍的簽約方的公司簡介。

第5章：癌症單株抗體合約目錄

• 癌症單株抗體合約目錄

第6章：癌症單株抗體合約：依技術類型分類

• 合約目錄
• 合約目錄：按公司名稱（A-Z）列出的癌症單株抗體合約
• 合約目錄：按合約類型分類的癌症單株抗體合約
• 合約目錄：按治療領域分類的癌症單株抗體合約
• 合約類型的定義
• 關於 Biopharma Research Ltd.
• 關於當前合作夥伴關係
• 關於現行協議
• Current Partnering 最新報告列表

The definitive benchmark for cancer monoclonal antibody dealmaking

Cancer monoclonal antibody partnering is driven by targeted biologic therapies, with deal structures reflecting the continued evolution of antibody-based approaches across oncology indications.

This report provides a comprehensive and structured analysis of 650+ cancer monoclonal antibody collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how monoclonal antibody deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by development stage, antibody type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a highly competitive and innovation-driven oncology landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within monoclonal antibody partnerships, particularly in areas involving differentiated biologics and targeted treatment strategies.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark oncology biologics transactions
• Prepare for negotiations with well-defined market context
• Evaluate licensing and co-development opportunities
• Support internal strategy with robust, defensible data
• What's included
• 650+ cancer monoclonal antibody collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and antibody type)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for cancer monoclonal antibody dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how monoclonal antibody partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer monoclonal antibody dealmaking

• 2.1. Introduction
• 2.2. Cancer monoclonal antibody deals over the years
• 2.3. Most active cancer monoclonal antibody dealmakers
• 2.4. Cancer monoclonal antibody deals by deal type
• 2.5. Cancer monoclonal antibody deals by therapy area
• 2.6. Cancer monoclonal antibody deals by industry sector
• 2.7. Deal terms for cancer monoclonal antibody deals
  • 2.7.1 Cancer monoclonal antibody deals headline values
  • 2.7.2 Cancer monoclonal antibody deal upfront payments
  • 2.7.3 Cancer monoclonal antibody deal milestone payments
  • 2.7.4 Cancer monoclonal antibody royalty rates

Chapter 3 - Leading cancer monoclonal antibody deals

• 3.1. Introduction
• 3.2. Top cancer monoclonal antibody deals by value

Chapter 4 - Most active cancer monoclonal antibody dealmakers

• 4.1. Introduction
• 4.2. Most active cancer monoclonal antibody dealmakers
• 4.3. Most active cancer monoclonal antibody deals company profiles

Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cancer monoclonal antibody contracts dealmaking directory

Chapter 6 - Cancer monoclonal antibody dealmaking by technology type

• Deal directory
• Deal directory - Cancer monoclonal antibody deals by company A-Z
• Deal directory - Cancer monoclonal antibody deals by deal type
• Deal directory - Cancer monoclonal antibody deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cancer monoclonal antibody deals since 2016
• Figure 2: Active cancer monoclonal antibody dealmaking activity since 2016
• Figure 3: Cancer monoclonal antibody deals by deal type since 2016
• Figure 4: Cancer monoclonal antibody deals by therapy area since 2016
• Figure 5: Cancer monoclonal antibody deals by industry sector since 2016
• Figure 6: Cancer monoclonal antibody deals with a headline value
• Figure 7: Cancer monoclonal antibody deals with an upfront value
• Figure 8: Cancer monoclonal antibody deals with a milestone value
• Figure 9: Cancer monoclonal antibody deals with a royalty rate value
• Figure 10: Top cancer monoclonal antibody deals by value since 2016
• Figure 11: Most active cancer monoclonal antibody dealmakers since 2016
• Figure 12: Cancer monoclonal antibody deals by technology type since 2016